Ritlecitinib plus light therapy for vitiligo
Part of Skin clinical trials.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-segmental vitiligo (the most common type, affecting both sides of the body).
- The vitiligo should cover between 4% and 60% of your body (not counting palms, soles, or top of feet).
- At least 0.5% of your face must be affected by vitiligo.
- You must not have taken any oral JAK inhibitor (like Xeljanz, Rinvoq, or Olumiant) before.
- You cannot have had phototherapy (like narrow-band UVB) within 8 weeks before starting the study.
- You must be willing to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a cream called ruxolitinib works for vitiligo in real-world conditions. It looks at what factors might make the treatment more or less effective.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
This trial tests a new treatment for non-segmental vitiligo that uses a special liquid made from stem cells, applied through tiny needle pricks or small injections, alongside standard light therapy. It may help restore pigment to white patches with fewer side effects than traditional treatments.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This study tests whether adding a pill called apremilast to narrowband UVB light therapy works better than light therapy alone for vitiligo. It may help repigment the skin more effectively.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.